首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy.
【24h】

Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy.

机译:在非照射和非清髓条件下,通过同时进行胰岛和骨髓移植,诱导对糖尿病NOD小鼠中MHC匹配的同种异体胰岛移植物的耐受性。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Human type 1 diabetes is associated with defects in the hematopoietic stem cells. Simultaneous donor islet and bone marrow transplantation may be an ideal therapeutic approach for inducing tolerance to islet allogeneic antigens and restoring self-tolerance to islet autoimmune antigens. METHODS: Using a nonobese diabetic (NOD) mouse model of human type 1 diabetes, we investigated whether tolerance to MHC-matched allogeneic islet grafts from male nonobese diabetes-resistant (NOR) donors can be induced in female NOD recipients by simultaneous islet and bone marrow transplantation under fludarabine phosphate-based nonmyeloablative and irradiation-free conditioning therapy. Donor-specific chimerism in the peripheral blood of tolerant mice (n=7) was measured by semiquantitative polymerase chain reaction for a male-specific marker (SRY). RESULTS: Donor-specific tolerance to NOR islet grafts was induced in all diabetic NOD mice after simultaneous islet and bone marrow transplantation and treated with fludarabine phosphate, cyclophosphamide, anti-mouse lymphocyte serum, and rapamycin. At 100 days and 200 days after transplantation, the average percentage of male NOR marker in DNA derived from the peripheral blood of NOD recipients that had long-term islet graft survival was over 10%. CONCLUSION: Our data suggest that this approach may induce donor-specific tolerance in clinical islet transplantation and living-related donor solid organ transplantation.
机译:背景:人类1型糖尿病与造血干细胞缺陷有关。供体胰岛和骨髓移植同时进行可能是诱导对胰岛同种异体抗原的耐受性和恢复对胰岛自身免疫抗原的自我耐受性的理想治疗方法。方法:使用人类1型糖尿病的非肥胖糖尿病(NOD)小鼠模型,我们调查了雌性NOD接受者能否同时通过胰岛和骨骼诱导对雄性非肥胖抗糖尿病(NOR)供体的MHC匹配同种异体胰岛移植物的耐受性基于氟达拉滨磷酸盐的非清髓和无辐射调理疗法进行的骨髓移植。通过针对男性特异性标记物(SRY)的半定量聚合酶链反应测量耐受小鼠(n = 7)外周血中的供体特异性嵌合体。结果:在所有胰岛NOD小鼠同时进行胰岛和骨髓移植后,诱导了其对NOR胰岛移植物的特异性耐受,并用氟达拉滨磷酸酯,环磷酰胺,抗小鼠淋巴细胞血清和雷帕霉素治疗。移植后100天和200天,来自具有长期胰岛移植存活率的NOD受体外周血DNA的男性NOR标记平均百分比超过10%。结论:我们的数据表明这种方法可能在临床胰岛移植和与生活有关的供体实体器官移植中诱导供体特异性耐受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号